Search

Displaying results 4471 - 4480 of 8700 in total
  1. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response.

  2. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.

    Categories: Experimental Unapproved Treatments for COVID-19, Cytochrome P-450 Substrates
  3. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  4. Drug

    19-Nor-5-androstenedione

    go.drugbank.com/drugs/DB01443
    ExperimentalIllicit

    It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.

  5. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because it can prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy. … Droloxifene may have an effect on bone and breast tissue because it induces apoptosis.

  6. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  7. Drug

    Nedocromil

    go.drugbank.com/drugs/DB00716
    Approved

    A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.

    Categories: Drugs for Obstructive Airway Diseases
  8. Drug

    L-threonic acid

    go.drugbank.com/drugs/DB11192
    ApprovedInvestigational

    Mixtures: EnBrace HR
  9. Drug

    KOS-2187

    go.drugbank.com/drugs/DB05946
    Experimental

    KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease

  10. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55. … JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.